Vivimed Labs share price
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.64down ₹0.11 (1.91%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹5.75.
29 Oct: open ₹5.65, high ₹5.65, low ₹5.64
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,884
Results
Consolidated; ₹ crore.Vivimed Labs quarterly results
Quarter to Mar 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹12 Crdown 24.95%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹146 CrQuarter to Dec 2025: −₹17 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −1,217.0%
Revenue by quarter
Peak revenue ₹37 Cr, quarter to Dec 2024; lowest ₹12 Cr, quarter to Mar 2026
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Net profit | −15 | −5 | −6 | −5 | −5 | −7 | −17 | −146 |
| Net margin | −51.9% | −20.8% | −16.4% | −20.1% | −25.7% | −35.4% | −103.5% | −1,217.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹70 Crdown 39.80%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹175 CrYear to Mar 2025: −₹31 Cr
- Net margin
- −250.6%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 7 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2019, the company reports a discontinued business.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Net profit | 222 | 78 | 115 | −109 | −78 | −68 | −329 | −45 | −31 | −175 |
| Net margin | 15.2% | 6.6% | – | −10.3% | −9.0% | −28.5% | −175.6% | −30.5% | −27.1% | −250.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2019: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMA, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: no results for a period ending in the last six months, or nine for a company filing half-yearly. Not shown, P/B: no results for a period ending in the last six months, or nine for a company filing half-yearly. Its history crosses a change of basis in the accounts in the year to Mar 2019: days before it are of the company before the change.Vivimed Labs PE ratio and valuation
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 72% of 1,768 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.48%
Vivimed Labs competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Vivimed Labs in market cap.Healthcare companies
Vivimed Labs is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sunil HealthcareSUNLOC | 63 | 17.56 | 0.90 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
 Rekvina LaboratoriesVINRKLB | 62 | – | – | – | – | – | −139.0% | 0.00% |
 PhaarmasiaPHRMASI | 61 | 3.44 | 2.75 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 48 | 98.87 | 2.22 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
 Mangalam Drugs and OrganicsMANGALAM | 46 | – | 0.45 | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 45 | – | 0.85 | −15.6% | – | −22.8% | −6.3% | 0.00% |
 Vasundhara RasayansVRL | 45 | 7.57 | 1.09 | +3.5% | +49.9% | 15.4% | 13.3% | 1.42% |
 Vista PharmaceuticalsVISTAPH | 40 | – | 1.09 | −60.4% | – | −28.7% | −32.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Vivimed Labs dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 19 Sep 2018 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.40 |
| 21 Sep 2017 | Final | ₹0.40 |
| 24 Sep 2014 | Final | ₹3.00 |
| 24 Sep 2013 | Final | ₹3.00 |
| 21 Sep 2012 | Final | ₹3.00 |
| 26 Sep 2011 | Final | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Vivimed Labs announcements
Oct 2026
22 Oct · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.15 Oct · Board meeting
Sep 2026
28 Sep · Updates
26 Sep
Aug 2026
Vivimed Labs share price by year
Each calendar year to 2025.Vivimed Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 17.67 | – | 26.60 | 17.67 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 18 Dec 2025.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 5.75 | 5.75 | 5.75 | 5.75 | 5.75 | 348 |
| 27 Oct 2026 | 5.90 | 5.90 | 5.86 | 5.86 | 5.89 | 26,481 |
| 26 Oct 2026 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 15,247 |
| 23 Oct 2026 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 75 |
| 22 Oct 2026 | 6.30 | 6.30 | 6.21 | 6.21 | 6.28 | 12,106 |
| 21 Oct 2026 | 6.35 | 6.40 | 6.33 | 6.33 | 6.36 | 12,147 |
| 19 Oct 2026 | 6.46 | 6.46 | 6.45 | 6.45 | 6.45 | 4,193 |
| 16 Oct 2026 | 6.70 | 6.70 | 6.58 | 6.58 | 6.60 | 14,210 |
| 15 Oct 2026 | 6.84 | 6.84 | 6.71 | 6.71 | 6.79 | 4,256 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 18 Dec 2025 | Price move | – | This is the share's first trade after a corporate action (Annual General Meeting, ex-date 27 Dec 2024), and the action's terms do not account for the move. Earlier prices are not shown. |
| 20 Jun 2022 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 6 Apr 2016 | Split | 0.2000 | Each share became 5. |
| 26 Jul 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- VIVIMEDLAB
- BSE code
- 532660
- ISIN
- INE526G01021
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.vivimedlabs.com
- CIN
- L02411KA1988PLC009465
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1988
- Registered office
- Plot No 78 - A Kolhar Industrial Area, Bidar 585403, Karnataka
- Share registrar
- Aarthi Consultants Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments